Coare Biotechnology is focused on developing innovative therapeutic technologies aimed at targeting cancer stem cells and the metastatic processes associated with them. Their approach includes the use of immunotherapy and nanomedicine, which are currently in various stages of development. The company emphasizes the importance of eradicating cancer stem cells to improve treatment outcomes for patients suffering from solid tumors.

A key component of Coare's research is the protein DCLK1, which is associated with tumor stemness in various solid tumors. DCLK1 plays a critical role in tumorigenesis and epithelial-mesenchymal transition (EMT), and its elevated levels have been linked to poor survival rates in cancer patients. Research indicates that downregulating DCLK1 can inhibit the invasion and migration of cancer cells in several types of solid tumors, including pancreatic, colon, kidney, ovarian, and breast cancers. This understanding underpins Coare's therapeutic development program, which aims to target DCLK1-expressing cells to enhance treatment efficacy for epithelial solid tumors.

United States

COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now.

Coare Biotechnology

Company Details